All In Biotech

Drug Trial Radar · NCT01515696

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study

Last checked: Nov 19, 2026Latest source record: Jul 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

96

Actual

Start

Oct 2007

Primary completion

Oct 2010

Study completion Feb 2011

Sponsor

Lead sponsor
Nadja Haiden,MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, up to 24 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population.

Conditions

  • Meconium Ileus
  • Very Low Birth Weight Infant

Interventions

  • GastrografinDrug

    Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.

  • Sterile waterDrug

    Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Complete Meconium Evacuation in DaysTime frame: days of life until until the complete meconium evacuation from birth up to 40 days of life

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.